Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating XBiotech for potential violations of securities laws

Core Viewpoint - XBiotech Inc. is under investigation for potential securities fraud following the announcement of a pause in its Phase 2 rheumatoid arthritis program for the drug candidate Natrunix due to failure to meet primary endpoints and irregularities in the study [1][2][3] Group 1: Company Developments - On December 23, 2024, XBiotech announced the pause of its Phase 2 rheumatoid arthritis program for Natrunix, citing failure to meet primary endpoints and substantial irregularities in the study [2] - The irregularities included issues at the highest enrolling clinical sites, with multiple subjects being enrolled more than once, complicating the interpretation of the study results [3] - Following the announcement, XBiotech's stock price fell over 29%, dropping from $6.38 to $4.50 per share [4] Group 2: Legal Investigation - Wolf Haldenstein Adler Freeman & Herz LLP is investigating claims on behalf of XBiotech investors regarding potential securities fraud by the company and its officers and/or directors [1] - The firm has a strong reputation in prosecuting securities class actions and derivative litigation across various courts in the United States [5]